Total Funding
87
71
Total FundingSeed raised
Growth Score 87 in past quarter
-4 pts
Heat Score 71 in past quarter
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
64075
Entheos Labs advances psychedelic medicines to treat mental health conditions like schizophrenia and Alzheimer's disease.
Jerrold Rosenbaum: Chief Medical AdvisorPast Role: Massachusetts General Hospital, Chief of Psychiatry- Stephen Haggarty: Chief Science Advisor
About the Company
Entheos Labs focuses on advancing the neuroscience of psychedelic medicines to address unmet medical needs in mental health. The company is dedicated to discovering, developing, and deploying groundbreaking psychedelic compounds. Entheos Labs aims to create a pipeline of new chemical entities derived from various psychedelic materials to treat
conditions such as schizophrenia, Alzheimer's disease, and traumatic brain injury. The team consists of scientific experts and business leaders committed to reshaping the future of mental health treatment.